Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

United Therapeutics (UTHR) Accumulated Depreciation & Amortization (2016 - 2025)

United Therapeutics (UTHR) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $85.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 18.07% to $85.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.6 million through Dec 2025, up 18.07% year-over-year, with the annual reading at $85.6 million for FY2025, 18.07% up from the prior year.
  • Accumulated Depreciation & Amortization hit $85.6 million in Q4 2025 for United Therapeutics, up from $62.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $85.6 million in Q4 2025 to a low of $12.5 million in Q1 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $38.4 million across 5 years, with a median of $37.7 million in 2021.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: decreased 0.4% in 2021 and later skyrocketed 36.28% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $49.9 million in 2021, then increased by 2.81% to $51.3 million in 2022, then increased by 3.7% to $53.2 million in 2023, then skyrocketed by 36.28% to $72.5 million in 2024, then increased by 18.07% to $85.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for UTHR at $85.6 million in Q4 2025, $62.8 million in Q3 2025, and $40.9 million in Q2 2025.